ADiTx Therapeutics, Inc. Appoints Dolly B. Tyan as Senior Vice President of Clinical Development - Transplantation
January 29, 2021 at 09:24 am
Share
Aditx Therapeutics, Inc. announced the appointment of Dr. Dolly B. Tyan as Senior Vice President of Clinical Development – Transplantation. In this role, Dr. Tyan will be overseeing Aditxt’s therapeutic program for organ rejection including advancing current candidates towards clinical trials and developing new products for new applications. Dr. Tyan will begin her work at Aditxt by advancing the Company’s proprietary technology, Apoptotic DNA Immunotherapy™ (ADi™), which is designed to retrain the immune system to induce tolerance, in the field of organ transplantation. The initial focus is on skin allografts. In this role she will join Dr. Friedrich Kapp, MD, PhD, who is leading Aditxt’s Autoimmunity therapeutic program, to guide the clinical advancement of the therapeutic division of the Company.
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
ADITXT, INC. 
